In metastatic prostate cancer, the maturation of osteoclast is quickened following CXCL1 stimulation, and this action has been shown to be blocked upon treatment with neutralizing antibodies against CXCL1 [247]. This evidence concerns the gene CXCL1 and metastatic prostate carcinoma.